1 INTRODUCTION
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OFPARKINSON’S DISEASE TREATMENT MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET SNAPSHOT
3.2 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET REVENUE, 2017– 2025(US$ MN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 COMPETITIVE LANDSCAPE
4.6 COMPANY MARKET SHARE ANALYSIS %, (2017)
4.7 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 CARBIDOPA/LEVODOPA,
5.3 DOPAMINE
5.4 RECEPTOR
5.5 AGONISTS,
5.6 MAO INHIBITORS
5.7 COMT INHIBITORS,
5.8 ANTICHOLINERGICS,
5.9 OTHER DRUGS
5.10
6 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 OVERVIEW
6.2 HOSPITALS
6.3 HEALTHCARE INSTITUTES
6.4 OTHERS
7 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY GEOGRAPHY
7.1 NORTH AMERICA
7.1.1 MARKET DYNAMICS
7.1.1.1 DRIVERS
7.1.1.2 RESTRAINTS
7.1.1.3 OPPORTUNITY
7.1.2 U.S.
7.1.3 CANADA
7.1.4 MEXICO
7.2 EUROPE
7.2.1 MARKET DYNAMICS
7.2.1.1 DRIVERS
7.2.1.2 RESTRAINTS
7.2.1.3 OPPORTUNITY
7.2.2 U.K.
7.2.3 FRANCE
7.2.4 GERMANY
7.2.5 SPAIN
7.2.6 REST OF EUROPE
7.3 ASIA PACIFIC
7.3.1 MARKET DYNAMICS
7.3.1.1 DRIVERS
7.3.1.2 RESTRAINTS
7.3.1.3 OPPORTUNITY
7.3.2 INDIA
7.3.3 CHINA
7.3.4 JAPAN
7.3.5 REST OF ASIA PACIFIC
7.4 MIDDLE EAST AND AFRICA
7.4.1 MARKET DYNAMICS
7.4.1.1 DRIVERS
7.4.1.2 RESTRAINTS
7.4.1.3 OPPORTUNITY
7.4.2 SOUTH AFRICA
7.4.3 REST OF MIDDLE EAST AND AFRICA
7.5 LATIN AMERICA
7.5.1 MARKET DYNAMICS
7.5.1.1 DRIVERS
7.5.1.2 RESTRAINTS
7.5.1.3 OPPORTUNITY
7.5.2 BRAZIL
7.5.3 REST OF LATIN AMERICA
8 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY COMPANY
8.1 INTRODUCTION
8.2 TEVA
8.2.1 BUSINESS OVERVIEW
8.2.2 PRODUCTS & SERVICES
8.2.3 KEY STRATEGY
8.2.4 RECENT DEVELOPMENTS
8.2.5 SWOT ANALYSIS
8.3 SUN PHARMA
8.3.1 BUSINESS OVERVIEW
8.3.2 PRODUCTS & SERVICES
8.3.3 KEY STRATEGY
8.3.4 RECENT DEVELOPMENTS
8.3.5 SWOT ANALYSIS
8.4 NOVARTIS A.G
8.4.1 BUSINESS OVERVIEW
8.4.2 PRODUCTS & SERVICES
8.4.3 KEY STRATEGY
8.4.4 RECENT DEVELOPMENTS
8.4.5 SWOT ANALYSIS
8.5 ABBVIE
8.5.1 BUSINESS OVERVIEW
8.5.2 PRODUCTS & SERVICES
8.5.3 KEY STRATEGY
8.5.4 RECENT DEVELOPMENTS
8.5.5 SWOT ANALYSIS
8.6 GSK MERCK
8.6.1 BUSINESS OVERVIEW
8.6.2 PRODUCTS & SERVICES
8.6.3 KEY STRATEGY
8.6.4 RECENT DEVELOPMENTS
8.6.5 SWOT ANALYSIS
8.7  IMPAX LABORATORIES
8.7.1 BUSINESS OVERVIEW
8.7.2 PRODUCTS & SERVICES
8.7.3 KEY STRATEGY
8.7.4 RECENT DEVELOPMENTS
8.7.5 SWOT ANALYSIS
8.8 VALEANT PHARMACEUTICALS
8.8.1 BUSINESS OVERVIEW
8.8.2 PRODUCTS & SERVICES
8.8.3 KEY STRATEGY
8.8.4 RECENT DEVELOPMENTS
8.8.5 SWOT ANALYSIS
8.9 ARCADIA
8.9.1 BUSINESS OVERVIEW
8.9.2 PRODUCTS & SERVICES
8.9.3 KEY STRATEGY
8.9.4 RECENT DEVELOPMENTS
8.9.5 SWOT ANALYSIS
8.10 DR. REDDY’S
8.10.1 BUSINESS OVERVIEW
8.10.2 PRODUCTS & SERVICES
8.10.3 KEY STRATEGY
8.10.4 RECENT DEVELOPMENTS
8.10.5 SWOT ANALYSIS